Jade Biosciences (JBIO) Stifel Virtual Immunology and Inflammation Forum summary

Company overview and strategy

• Focused on developing best-in-class therapeutics for autoimmune diseases, leveraging three antibody assets from Paragon Therapeutics with advanced protein engineering and half-life extension expertise.

• Lead program is Jade 101, an anti-APRIL antibody targeting IgA nephropathy (IGAN), aiming for infrequent subcutaneous dosing.

• Recently became a clinical-stage company after dosing the first cohort in a phase one trial; first-in-human data expected in the first half of next year.

• Completed a reverse merger and secured financing to fund operations and advance three programs through 2027.

• Ended last quarter with $221 million in cash, supporting development of Jade 101, 201, and 03.

IGAN treatment landscape and evolving standards

• IGAN treatment has shifted with new therapies; current standard includes ACE inhibitors/ARBs, SGLT2 inhibitors, and endothelin receptor antagonists.

• Updated KDIGO guidelines will soon recommend all patients receive agents proven to reduce pathogenic IgA, positioning anti-APRILs as frontline therapy.

• Lower proteinuria thresholds (0.5 g/day) are emphasized, with further treatment added if targets are not met.

Anti-APRIL mechanism and clinical differentiation

• APRIL inhibition drives efficacy in IGAN, with selective anti-APRILs preferred over dual BAFF/APRIL or BAFF-only agents due to specificity and safety.

• Jade 101 designed for ultra-high binding affinity (50 femtomolar KD), 750–2,000 times higher than competitors, enabling full APRIL suppression at lower doses.

• Incorporates YTE Fc modifications for half-life extension, supporting dosing no more frequently than every eight weeks.

• Novel epitope selection prevents large immune complex formation, reducing immunogenicity and target-mediated drug disposition.